Pharmaceuticals, Biotechnology and Life Sciences
WARREN, N.J.–(BUSINESS WIRE)–Tevogen Bio Holdings (‘Tevogen Bio’) (Nasdaq: TVGN), congratulates Victor Sordillo PE, CSP, MBA, on his recent appointment as…
Increasing physician interest, newly approved reimbursement code driving growth SAN ANTONIO–(BUSINESS WIRE)–#BIAF—bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company…
DUBLIN–(BUSINESS WIRE)–The “Phosphodiesterase-4 (PDE4) Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast – 2034” report has been added…
SARASOTA, Fla.–(BUSINESS WIRE)–Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological…
– First PAH Patient Dosed in Ongoing Registrational Phase 3 PROSERA Study – – Inclusion of Japan in Phase 3…
– Study Met the Primary Endpoint Demonstrating Clinically Significant Systolic Blood Pressure Reductions at Month 3 When Zilebesiran Was Added…
Last patient randomized in Phase 2a PICASSO trial, sponsored by AP-HP in collaboration with MaaT Pharma, INRAE and Institut Gustave…
NEW YORK & SUZHOU, China–(BUSINESS WIRE)–AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with…
— ALPHA-STAR Trial of STAR-0215 Initial Proof-of-Concept Data in HAE Patients Expected Q1 2024 — — STAR-0310, Potential Best-in-Class OX40…
DUBLIN–(BUSINESS WIRE)–$PRTA #prothena–Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on…